国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
1期
80-82
,共3页
美托洛尔%曲美他嗪%冠心病%心力衰竭
美託洛爾%麯美他嗪%冠心病%心力衰竭
미탁락이%곡미타진%관심병%심력쇠갈
Metoprolol%Trimetazidine%Coronary heart disease%Cardiac failure
目的 观察美托洛尔与曲美他嗪联合治疗冠心病心力衰竭的临床疗效,探讨其临床价值.方法 将给与常规治疗的48例冠心病并心力衰竭患者视为对照组,采用美托洛尔联合曲美他嗪治疗的48例冠心病并心力衰竭患者视为观察组,观察两组患者临床疗效及心功能改善情况.结果 观察组总有效率为95.83％,明显高于对照组的83.33％(P＜0.05)；观察组治疗6个月后LVEF明显高于对照组(P＜0.05),LVESD及LVEDD均明显低于对照组(P＜0.05).结论 美托洛尔联合曲美他嗪治疗冠心病心力衰竭具有疗效好、见效快、药效持久等优点,可作为目前治疗冠心病心力衰竭的一种较佳治疗方案.
目的 觀察美託洛爾與麯美他嗪聯閤治療冠心病心力衰竭的臨床療效,探討其臨床價值.方法 將給與常規治療的48例冠心病併心力衰竭患者視為對照組,採用美託洛爾聯閤麯美他嗪治療的48例冠心病併心力衰竭患者視為觀察組,觀察兩組患者臨床療效及心功能改善情況.結果 觀察組總有效率為95.83％,明顯高于對照組的83.33％(P＜0.05)；觀察組治療6箇月後LVEF明顯高于對照組(P＜0.05),LVESD及LVEDD均明顯低于對照組(P＜0.05).結論 美託洛爾聯閤麯美他嗪治療冠心病心力衰竭具有療效好、見效快、藥效持久等優點,可作為目前治療冠心病心力衰竭的一種較佳治療方案.
목적 관찰미탁락이여곡미타진연합치료관심병심력쇠갈적림상료효,탐토기림상개치.방법 장급여상규치료적48례관심병병심력쇠갈환자시위대조조,채용미탁락이연합곡미타진치료적48례관심병병심력쇠갈환자시위관찰조,관찰량조환자림상료효급심공능개선정황.결과 관찰조총유효솔위95.83％,명현고우대조조적83.33％(P＜0.05)；관찰조치료6개월후LVEF명현고우대조조(P＜0.05),LVESD급LVEDD균명현저우대조조(P＜0.05).결론 미탁락이연합곡미타진치료관심병심력쇠갈구유료효호、견효쾌、약효지구등우점,가작위목전치료관심병심력쇠갈적일충교가치료방안.
Objeective To investigate the clinical efficacy of combination therapy with metoprolol and trimetazidine in the treatment of cardiac failure due to coronary heart disease (CHD).Meyhods 96 patients with cardiac failure due to CHD divided study group and control group,48 for each group.The control group received routine comprehensive treatment,while the study group received metoprolol combined with trimetazidine.The clinical efficacy and improvement in cardiac function were observed in the two groups.Results The total effectiveness rate was significantly higher in the study group than in the control group (95.83％ vs.83.33％,P＜0.05).Six months after treatment,LVEF was significantly greater while LVESD and LVEDD were markedly smaller in the study group than in the control group (P＜0.05 for all comparisons).Conclusions Combination therapy with metoprolol and trimetazidine is efficacious and has a rapid onset of action and a longer-lasting action.It can be used as an ideal therapeutic regimen for cardiac failure due to coronary heart disease.
